News

The results of two more studies on the Russian antiviral drug Kagocel have recently been published in the international clinical trial database ClinicalTrials.gov.

On December 16, the antiviral drug Kagocel was for the seventh time proclaimed winner of the annual Russian Pharma Awards in the category "Antiviral agent No. 1 in Russia against influenza and ARVI for adults and children from the age of three".

The Nearmedic group of companies has realized a large-scale charity event by passing the antiviral drug Kagocel over to the country's medical institutions.

Kagocel wins the Choice of the Year contest in Belarus again.

The commercial Family Law created by the marketing team of the antiviral brand Kagocel, won silver at the MedMen Healthcare Creative Awards.

Results of two post-registration clinical trials of the antiviral drug Kagocel effectiveness were published in the international database of clinical trials ClinicalTrials.gov.

On November 12, 2020, the Arbitration Court of the city of Saint Petersburg and the Leningrad region satisfied the claim of Nearmedic Pharma LLC to protect its business reputation. The claim was induced by the material made public on 28.01.2020 in Doctor Peter online magazine and containing untrue information about the composition and non-existent side effects of the company's antiviral drug Kagocel.

The Nearmedic Pharma company has launched a cashback program for the popular antiviral drug Kagocel. The promotion program has been developed in collaboration with the Wavemaker advertising agency.

The antiviral drug Kagocel will once again become the official sponsor of the ISU European Figure Skating Championships® and ISU World Figure Skating Championships® to be held in 2021. The brand has been supporting those sports events since 2018.

For the second year in a row, Kagocel was recognized by Smartpharma Awards 2020 as the best influenza and ARVI antiviral agent in Russia for adults and children from 3 years old. The award ceremony was held in a solemn atmosphere, but with all the necessary precautions related to the new coronavirus pandemic.

The 48th Central Research Institute of the Russian Federation Ministry of Defense (CRI 48) has studied the antiviral activity of the drug Kagocel in relation to a new pandemic strain of SARS-CoV-2 in the course of in vitro experiments.

Recently, social networks and a number of media outlets have been ever more frequently spreading knowingly false and absurd speculations about the composition, non-core properties and non-existent side effects, as well as adverse effects associated with the Kagocel^® antiviral drug.

The antiviral brand Kagocel keeps up the tradition of supporting sports events.

In the framework of the Smartpharma Awards 2019, the Gazprom-Media sales house, title partner of the award, gave Nearmedic  a special award "For innovative approach in cross-media advertising", thus praising marketing activities of the company's brand Kagocel.

On May 22, 2019 Kagocel was recognized as the best drug in the nomination "Antiviral agent No.1 in Russia against influenza and SARS in adults and children from 3 years" according to Smartpharma® Awards 2019.  

On May 24, 2019, the ceremony of awarding the participants of the program "Best social projects of Russia" was held.

The project "When your girlfriend has fallen ill" received a bronze award in the PR category at the White Square, the largest creative arts festival in Central and Eastern Europe.

On March 18-24, the Japanese city of Saitama will host the ISU World Figure Skating Championships® 2019.

The Russian investment forum was held in Sochi on February 13-15, 2019.

On December 13, 2018, the 17th award ceremony of the Choice of the Year contest was held in Minsk.